Tocilizumab for the Management of Corticosteroid-Resistant Mild to Severe Graves’ Ophthalmopathy, a Report of Three Cases
- 20 November 2018
- journal article
- letter
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 28 (2) , 281-284
Abstract
Purpose: To discuss the use of tocilizumab in mild to severe Graves’ ophthalmopathy as corticosteroid-adjunctive therapy. Methods: Retrospective case reports. Results: Three patients with corticosteroid-resistant or advanced diplopia-associated Graves’ ophthalmopathy were subsequently treated with monthly intravenous tocilizumab at a dose of 8 mg/kg. None reported a past or present history of dysthyroidism. The adjunction of interleukin-6-receptor monoclonal antibody treatment was associated with a significant improvement in ocular symptoms, notably diplopia and proptosis, and functional prognosis in all patients, with one relapse approximately two months after the end of the treatment. Conclusion: These clinical reports confirm the relative efficacy and tolerability profile of intravenous tocilizumab in severe or corticosteroid-resistant Graves’ ophthalmopathy.Keywords
This publication has 11 references indexed in Scilit:
- Does rituximab improve clinical outcomes of patients with thyroid-associated ophthalmopathy? A systematic review and meta-analysisBMC Ophthalmology, 2018
- Tocilizumab as a steroid sparing agent for the treatment of Graves' orbitopathyAmerican Journal of Ophthalmology Case Reports, 2017
- Advances in treatment of active, moderate-to-severe Graves' ophthalmopathyThe Lancet Diabetes & Endocrinology, 2017
- THERAPY OF ENDOCRINE DISEASE: Endocrine dilemma: management of Graves’ orbitopathyEuropean Journal of Endocrinology, 2016
- Prevalence, Phenotype, and Psychosocial Well-Being in Euthyroid/Hypothyroid Thyroid-Associated OrbitopathyThyroid®, 2015
- Efficacy of B-Cell Targeted Therapy With Rituximab in Patients With Active Moderate to Severe Graves' Orbitopathy: A Randomized Controlled StudyThe Journal of Clinical Endocrinology & Metabolism, 2015
- Immunotherapy for Graves’ ophthalmopathyCurrent Opinion in Endocrinology, Diabetes and Obesity, 2014
- Treatment of Active Corticosteroid-Resistant Graves’ OrbitopathyOphthalmic Plastic & Reconstructive Surgery, 2014
- Euthyroid and primarily hypothyroid patients develop milder and significantly more asymmetrical Graves ophthalmopathyBritish Journal of Ophthalmology, 2009
- Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GOEuropean Journal of Endocrinology, 2008